Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleInflammation, Immunopharmacology, and Asthma

The In Vitro Pharmacology of GS-5759, A Novel Bifunctional Phosphodiesterase 4 Inhibitor and Long Acting β2-Adrenoceptor Agonist

Stacey L. Tannheimer, Eric A. Sorensen, Zhi-Hua Cui, Musong Kim, Leena Patel, William R. Baker, Gary B. Phillips, Clifford D. Wright and Michael Salmon
Journal of Pharmacology and Experimental Therapeutics April 2014, 349 (1) 85-93; DOI: https://doi.org/10.1124/jpet.113.210997
Stacey L. Tannheimer
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric A. Sorensen
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi-Hua Cui
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Musong Kim
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leena Patel
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William R. Baker
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary B. Phillips
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford D. Wright
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Salmon
Oncology/Inflammation Research (S.L.T., E.A.S., Z-H.C., C.D.W., M.S.), Medicinal Chemistry (M.K., L.P., W.R.B., G.B.P.), Gilead Sciences Inc., Seattle, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Inhaled long-acting β2-adrenoceptor agonists (LABA) that act as bronchodilators and the oral anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor roflumilast are both approved therapies for chronic obstructive pulmonary disease (COPD). Here we describe the activity of a novel, inhaled, bifunctional, small molecule (R)-6-[(3-{[4-(5-{[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}pent-1-yn-1-yl)phenyl]carbamoyl}phenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide (GS-5759), which has specific β2 agonist and PDE4 inhibitory activity. GS-5759 demonstrated potent and full agonist activity at β2 adrenoceptors (EC50 = 8 ± 4 nM) and is a potent inhibitor of the PDE4 enzyme (IC50 = 5 ± 3 nM). In cell assays, GS-5759 inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor α (TNFα) production in human peripheral mononuclear cells (PBMC) with an IC50 = 0.3 nM [confidence interval (CI) 0.1–0.6] and in human neutrophils formyl-methionyl-leucyl-phenylalanine (fMLP)-induced super oxide anion production with an IC50 = 3 nM (CI 0.8–8). The addition of the β2 antagonist ICI 118551 shifted the IC50 in these cell assays to 4 and 38 nM, respectively, demonstrating the contribution of both β2 agonist and PDE4 inhibitory activity to GS-5759. GS-5759 was also a potent inhibitor of profibrotic and proinflammatory mediator release from human lung fibroblasts. GS-5759 relaxed guinea pig airway smooth muscle strips precontracted with carbachol in a concentration-dependent manner with an EC50 = 0.5 µM (CI 0.2–2) and had slow dissociation kinetics with an Off T1/2 > 720 minutes at an EC80 concentration of 3 µM. GS-5759 is a novel bifunctional molecule with both potent β2 agonist and PDE4 inhibitor activity that could provide inhaled bronchodilator and anti-inflammatory therapy for COPD.

Footnotes

    • Received November 5, 2013.
    • Accepted February 7, 2014.
  • ↵1 Current affiliation: Merck Research Laboratories, Boston, Massachusetts.

  • This study was funded by Gilead Sciences, Inc.

  • Portions of this work were presented at the following meetings: Tannheimer SL, Wright CW, and Salmon M (2012) GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and long-acting β2-adrenoceptor agonist has anti-inflammatory and anti-remodeling activity in human lung fibroblasts; Sorensen EA, Tannheimer SL, Haran AC, Wright CW, and Salmon M (2012) GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and long-acting β2-adrenoceptor agonist, has potent anti-inflammatory activity in human monocytes and neutrophils; and Cui Z-H, Gentzler TT, and Salmon M (2012) GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and long-acting β2-adrenoceptor agonist, in vitro pharmacology on guinea pig tracheal smooth muscle strips. American Thoracic Society International Conference; 18–23 May 2012; San Francisco, CA; and Kim M, Patel L, Purvis LJ, Cui Z, Gentzler T, Salmon M, Sorensen R, Tannheimer S, and Phillps G (2012) Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of respiratory disease: (III) Discovery of GS-5759. 244th American Chemical Society National Meeting & Exposition; 19-23 Aug 2012; Philadelphia, PA.

  • dx.doi.org/10.1124/jpet.113.210997.

  • Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 349 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 349, Issue 1
1 Apr 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The In Vitro Pharmacology of GS-5759, A Novel Bifunctional Phosphodiesterase 4 Inhibitor and Long Acting β2-Adrenoceptor Agonist
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleInflammation, Immunopharmacology, and Asthma

In Vitro Pharmacology of GS-5759

Stacey L. Tannheimer, Eric A. Sorensen, Zhi-Hua Cui, Musong Kim, Leena Patel, William R. Baker, Gary B. Phillips, Clifford D. Wright and Michael Salmon
Journal of Pharmacology and Experimental Therapeutics April 1, 2014, 349 (1) 85-93; DOI: https://doi.org/10.1124/jpet.113.210997

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleInflammation, Immunopharmacology, and Asthma

In Vitro Pharmacology of GS-5759

Stacey L. Tannheimer, Eric A. Sorensen, Zhi-Hua Cui, Musong Kim, Leena Patel, William R. Baker, Gary B. Phillips, Clifford D. Wright and Michael Salmon
Journal of Pharmacology and Experimental Therapeutics April 1, 2014, 349 (1) 85-93; DOI: https://doi.org/10.1124/jpet.113.210997
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PK/PD of Dexamethasone in LPS-Challenged Rats
  • Expression of PAR2 in iKera to Model Atopic Dermatitis
  • Cholesterol Esterification and Acute Lung Injury
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics